These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35620314)

  • 21. A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study.
    Nishida T; Tsujii Y; Okamoto A; Tomita R; Higaki Y; Osugi N; Sugimoto A; Takahashi K; Mukai K; Nakamatsu D; Matsubara T; Hayashi S; Yamamoto M; Nakajima S; Fukui K; Inada M
    Digestion; 2020; 101(5):608-614. PubMed ID: 31288235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, safety and cost-effectiveness of vonoprazan vs Proton Pump Inhibitors in reflux disorders and H. pylori eradication: A literature review.
    Shehryar M; Ahmad RU; Kareem HK; Khan L; Ashraf MF; Hassan A; Saeed S; Tareen HK; Nazir DA; Ashraf MA
    Ann Med Surg (Lond); 2022 Oct; 82():104760. PubMed ID: 36268393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proton Pump Inhibitor-Related Gastric Mucosal Changes.
    Kim GH
    Gut Liver; 2021 Sep; 15(5):646-652. PubMed ID: 32327613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastric mucosal cracked and cobblestone-like changes resulting from proton pump inhibitor use.
    Miyamoto S; Kato M; Tsuda M; Matsuda K; Muranaka T; Abiko S; Ono M; Mizushima T; Omori S; Yamamoto K; Mabe K; Ono S; Kudo T; Shimizu Y; Sakamoto N
    Dig Endosc; 2017 May; 29(3):307-313. PubMed ID: 27859804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis.
    Shinozaki S; Kobayashi Y; Osawa H; Sakamoto H; Hayashi Y; Lefor AK; Yamamoto H
    Digestion; 2021; 102(3):319-325. PubMed ID: 31914442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of
    Kanu JE; Soldera J
    World J Gastroenterol; 2024 Mar; 30(9):1213-1223. PubMed ID: 38577188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case-control analysis of fundic gland polyps and proton-pump inhibitors. A pathologist's perspective.
    Velazquez-Dohorn M; López-Durand CF; Candanedo-González F; Araujo-Villalvazo EA; Gamboa-Domínguez A
    Rev Gastroenterol Mex (Engl Ed); 2020; 85(1):42-47. PubMed ID: 31126726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials.
    Yang C; Li S; Huang T; Lin H; Jiang Z; He Y; Yuan J; An H
    J Clin Pharm Ther; 2022 Jul; 47(7):897-904. PubMed ID: 35247003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study.
    Hamada K; Uedo N; Tonai Y; Arao M; Suzuki S; Iwatsubo T; Kato M; Shichijo S; Yamasaki Y; Matsuura N; Nakahira H; Kanesaka T; Yamamoto S; Akasaka T; Hanaoka N; Takeuchi Y; Higashino K; Ishihara R; Okada H; Iishi H; Fukui K; Shimokawa T
    J Gastroenterol; 2019 Feb; 54(2):122-130. PubMed ID: 29943163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.
    Ashida K; Sakurai Y; Nishimura A; Kudou K; Hiramatsu N; Umegaki E; Iwakiri K; Chiba T
    Aliment Pharmacol Ther; 2015 Sep; 42(6):685-95. PubMed ID: 26201312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Propensity score matching analysis: incidence and risk factors for "stardust" gastric mucosa, a novel gastric finding potentially induced by vonoprazan.
    Yoshizaki T; Morisawa T; Fujinami M; Matsuda T; Katayama N; Inoue K; Matsumoto M; Ikeoka S; Takagi M; Sako T; Momose K; Noda M; Eguchi T; Okada A
    Aliment Pharmacol Ther; 2021 Jan; 53(1):94-102. PubMed ID: 33159407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis.
    Simadibrata DM; Syam AF; Lee YY
    J Gastroenterol Hepatol; 2022 Dec; 37(12):2217-2228. PubMed ID: 36181401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with vonoprazan for 3 weeks is not inferior to 8 weeks for the management of gastric ESD: a multicenter noninferiority randomized study.
    Kato M; Hosoe N; Gotoda T; Kusano C; Kuramochi M; Yoshida H; Kimoto Y; Okamura Y; Imaeda H; Ito T; Miyamoto Y; Horii T; Mori H; Morohoshi Y; Ohno A; Kishino R; Kubosawa Y; Yoshimura K; Yahagi N; Kanai T
    J Gastroenterol; 2023 Apr; 58(4):358-366. PubMed ID: 36781490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
    Shin GY; Park JM; Hong J; Cho YK; Yim HW; Choi MG
    Am J Gastroenterol; 2021 Jun; 116(6):1211-1219. PubMed ID: 34074826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proton Pump Inhibitor Induction of Gastric Cobblestone-like Lesions in the Stomach.
    Takahari K; Haruma K; Ohtani H; Kiyoto S; Watanabe A; Kamada T; Manabe N; Hatano Y
    Intern Med; 2017 Oct; 56(20):2699-2703. PubMed ID: 28924108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori.
    Saito Y; Konno K; Sato M; Nakano M; Kato Y; Saito H; Serizawa H
    Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30669474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
    Kajihara Y; Shimoyama T; Mizuki I
    Scand J Gastroenterol; 2017 Feb; 52(2):238-241. PubMed ID: 27806639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.
    Gotoh Y; Ishibashi E; Honda S; Nakaya T; Noguchi C; Kagawa K; Murakami K
    Medicine (Baltimore); 2020 Mar; 99(11):e19520. PubMed ID: 32176102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of vonoprazan-based regimens compared with proton pump inhibitor-based regimens as first-line
    Kakiuchi T
    Front Pharmacol; 2023; 14():1216433. PubMed ID: 37538185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
    Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
    Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.